We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comparison of the efficacy and adherence of generic and brand-name entecavirs in chronic hepatitis B patients: a multicenter cohort study.
- Authors
Ying Xie; Hanqiu Zhan; Xiaohong Zhu; Yuan Li; Ruyi Tian; Jing Zhang; Shanshan Chen; Yanling Zhao
- Abstract
In the present study, we aimed to compare the efficacy and adherence of Runzhong® (generic drug, Chiatai Tianqing, Nanjing) and Baraclude® (branded drug, Bristol-Myers Squibb) in patients with chronic hepatitis B. We collected patient data from three hospitals within 48 weeks and compared the two groups by using the propensity-score matching method. A total of 4889 patients were enrolled in this study; 503 initiated a brand-name drug, and 4386 received a generic drug. There was no significant difference in the rates of CVR (complete virologic response) and VB (virologic breakthrough) between the Runzhong® group and Baraclude® group at 24 and 48 weeks. Similar results for HBeAg loss, medication possession ratio (MPR), and biological response were obtained. Age, gender (HR 0.909 (0.842-0.981)), normal baseline ALT rate (HR 0.789 (0.731-0.851)), HBeAg-positive rate, and baseline undetectable HBV DNA rate (HR 0.306 (0.234-0.399)) were independent factors for achieving CVR..
- Subjects
NANJING (Jiangsu Sheng, China); BRISTOL-Myers Squibb Co.; CHRONIC hepatitis B; GENERIC drugs; COHORT analysis
- Publication
Journal of Chinese Pharmaceutical Sciences, 2021, Vol 30, Issue 12, p986
- ISSN
1003-1057
- Publication type
Article
- DOI
10.5246/jcps.2021.12.085